SG11201605919YA - Agents for use in the treatment of retinal inflammation - Google Patents

Agents for use in the treatment of retinal inflammation

Info

Publication number
SG11201605919YA
SG11201605919YA SG11201605919YA SG11201605919YA SG11201605919YA SG 11201605919Y A SG11201605919Y A SG 11201605919YA SG 11201605919Y A SG11201605919Y A SG 11201605919YA SG 11201605919Y A SG11201605919Y A SG 11201605919YA SG 11201605919Y A SG11201605919Y A SG 11201605919YA
Authority
SG
Singapore
Prior art keywords
agents
treatment
retinal inflammation
retinal
inflammation
Prior art date
Application number
SG11201605919YA
Other languages
English (en)
Inventor
Florian Sennlaub
Xavier Guillonneau
Olivier Levy
José-Alain Sahel
Original Assignee
Université Pierre Et Marie Curie Paris 6 Upmc
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49998095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201605919Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université Pierre Et Marie Curie Paris 6 Upmc, Centre Nat Rech Scient filed Critical Université Pierre Et Marie Curie Paris 6 Upmc
Publication of SG11201605919YA publication Critical patent/SG11201605919YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201605919YA 2014-01-22 2015-01-22 Agents for use in the treatment of retinal inflammation SG11201605919YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14152189.8A EP2898896A1 (en) 2014-01-22 2014-01-22 Agents for use in the treatment of retinal inflammation
PCT/EP2015/051293 WO2015110556A1 (en) 2014-01-22 2015-01-22 Agents for use in the treatment of retinal inflammation

Publications (1)

Publication Number Publication Date
SG11201605919YA true SG11201605919YA (en) 2016-08-30

Family

ID=49998095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605919YA SG11201605919YA (en) 2014-01-22 2015-01-22 Agents for use in the treatment of retinal inflammation

Country Status (12)

Country Link
US (1) US10519232B2 (ja)
EP (2) EP2898896A1 (ja)
JP (1) JP6689484B2 (ja)
KR (1) KR102379006B1 (ja)
AU (1) AU2015208105A1 (ja)
BR (1) BR112016016901A2 (ja)
CA (1) CA2937591C (ja)
IL (1) IL246855A0 (ja)
MX (1) MX2016009600A (ja)
RU (1) RU2016133022A (ja)
SG (1) SG11201605919YA (ja)
WO (1) WO2015110556A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7199966B2 (ja) 2015-12-23 2023-01-06 ソルボンヌ ウニベルシテ ＣＤ１１ｂ／ＣＤ１８に対するＣＦＨの結合を阻害する薬剤、およびその使用
ITUB20169937A1 (it) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
AU2017223687A1 (en) * 2016-02-23 2018-08-09 Sesen Bio, Inc. IL-6 antagonist formulations and uses thereof
US11142548B2 (en) * 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
IL301762A (en) * 2020-10-07 2023-05-01 Line 6 Biotechnology Inc Methods and materials for the treatment of eye diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2914672B2 (ja) 1989-01-17 1999-07-05 中外製薬株式会社 Ｂｓｆ▲下２▼アンタゴニスト
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
JPH07324097A (ja) 1994-05-30 1995-12-12 Daicel Chem Ind Ltd インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
JPH08311098A (ja) 1995-05-22 1996-11-26 Daicel Chem Ind Ltd 新規ペプチド類およびそれを含有するインターロイキン６拮抗剤
US6001962A (en) 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
ATE391136T1 (de) 1998-06-18 2008-04-15 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
EP1572103A4 (en) * 2002-11-15 2008-02-13 Centocor Inc ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
CA2678735A1 (en) * 2007-02-26 2008-09-04 Santen Pharmaceutical Co., Ltd. Novel pyrrole derivative having ureido group and aminocarbonyl group as substituents
JP5424330B2 (ja) * 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
US20090082470A1 (en) 2007-09-24 2009-03-26 Rafal Farjo Stat3 inhibiting compositions and methods
CN102131774A (zh) * 2008-08-25 2011-07-20 参天制药株式会社 含有脲基、氨基羰基及可以具有取代基的二环式基团作为取代基的新型吡咯衍生物
EP2780022B2 (en) * 2011-11-14 2022-09-07 Astellas Institute for Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US20150051212A1 (en) 2012-03-28 2015-02-19 Regenerative Research Foundation Compositions And Methods For Inhibiting Drusen
CN104903349B (zh) * 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用

Also Published As

Publication number Publication date
BR112016016901A2 (pt) 2018-03-20
AU2015208105A1 (en) 2016-08-04
RU2016133022A (ru) 2018-02-26
JP6689484B2 (ja) 2020-04-28
EP3096781A1 (en) 2016-11-30
EP3096781B1 (en) 2022-11-02
JP2017505303A (ja) 2017-02-16
WO2015110556A1 (en) 2015-07-30
CA2937591C (en) 2022-09-06
US10519232B2 (en) 2019-12-31
EP2898896A1 (en) 2015-07-29
KR20160106667A (ko) 2016-09-12
US20160340424A1 (en) 2016-11-24
IL246855A0 (en) 2016-08-31
MX2016009600A (es) 2017-02-13
CA2937591A1 (en) 2015-07-30
KR102379006B1 (ko) 2022-03-28

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL283086A (en) Use of cannabidiol in the treatment of multiple sclerosis complex
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL247589A0 (en) Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
IL251904A0 (en) Epilimod for use in the treatment of melanoma
IL247969B (en) A medicinal component for use in the treatment of infections
HK1256164A1 (zh) 用於治療神經膠質瘤的製劑
IL246855A0 (en) Materials for use in the treatment of retinitis
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
HK1252811A1 (zh) 用於去勢治療相關症狀之治療的化合物